NCI Director's Report: Realities and opportunities for cancer research

W. Kimryn Rathmell, M.D., Ph.D.
Director, National Cancer Institute
91st Meeting of the NCI Council of Research Advocates (NCRA)
March 5, 2024

@NCIDirector @TheNCI

Today's Topics:

Brief introduction
 Budget outlook
 Research highlights
 Q&A



A little about me

Background in brief:

- Scientist
- Clinician, oncologist
- Educator/mentor
- Health care management and administration
- Leader
- Advocacy
- Basketball player (and aficionado)

Principles I value



Listening, openness



Teamwork, collaboration



Solving complex problems

Patient story



A story about advocacy, collaboration, and impact



Meeting and treating "Paul"





Connecting with advocates through social media

Think tank meeting



Creating RMC Alliance



IMPACT: Improved health outcomes, clinical trials, information, visibility, education, grants



Budget outlook



Where we are today



Potential lapses in appropriation averted: September 30, 2023 November 17, 2023 February 2, 2024 Current Continuing Resolution expires March 22 (halfway through the fiscal year).



Interim grant policies have been set. Final adjustments will be made when NCI receives a full-year appropriation.



NCI's budget is determined within the federal budget ecosystem

alongside many other national priorities

Appropriations bills under consideration


March 8

- Agriculture, Rural Development, FDA, and Related Agencies
- Commerce, Justice, Science, and Related Agencies
- Energy and Water Development
- Interior, Environment, and Related Agencies
- Military Construction, Veterans Affairs, and Related Agencies
- Transportation, Housing and Urban Development, and Related Agencies

March 22

- Defense
- Financial Services and General Government
- Homeland Security
- Labor, Health and Human Services, Education, and Related Agencies
- Legislative Branch
- State, Foreign Operations, and Related Programs

How NCI spends its budget



Major areas of NCI's work span more than one of the categories in the chart:

- Clinical trials
- Training & career development
- Basic science

These efforts are funded through multiple mechanisms and approaches, including:

- Intramural research
- Extramural research
- National networks
- Research project grants

What it would cost to make the most rapid progress against cancer

	NCI's Professional Judgment Budget Proposal	President's Budget Proposal for NCI	Actual NCI Budget
FY 2024	\$9.988B	 \$7.8B 6.9% increase of total NCI budget (compared to FY23 enacted) Includes \$216M for Cancer Moonshot 	?
FY 2025	\$11.466B	?	?

NCI Fiscal Year 2025 Professional Judgment Budget Proposal



Leading Progress against Cancer

NCI Fiscal Year 2025 Professional Judgment Budget Proposal

View the budget proposal and the Director's Message: www.cancer.gov/research/leading-progress

Highlighted Scientific Opportunities

- Improving patients' lives through symptom science research
- Revolutionizing cancer clinical trials
- Clarifying the impact of the environment on cancer risk
- Harnessing the power of cancer data
- Unraveling the complexity of cancer metastasis


NCI has been funding more awards year over year

8,000 7,000 6,000 Dollars (in millions) 5,000 4,000 3,000 2,000 1,000 0 2022 2019 2020 2021 2023 **Fiscal Year Cancer Moonshot funding** Enacted

NCI Budget History (appropriations)

FY19 - FY23

NCI Grant Awards (competing and non-competing) FY19 – FY23





12

A "flat" budget is not truly flat – it is a reduction

Why?

- End of 21st Century Cures Act funding for the Cancer MoonshotSM
- Research costs and salaries
 increase (COLA)
- Non-negotiable expenses for NCI increase each year by \$75M to \$100M
- RPG cost increases \$250M annually to fully fund at current levels

Available levers to manage constrained budget:

Research Project Grants (RPGs)	•	Decrease the "payline" for new awards Fund non-competing awards < 100%
Cancer Center Support Grants (CCSGs)	•	Forgo increases for competing renewals Decreases to non-competing CCSGs
Cancer Training Awards	•	Fewer new awards (F's, K's, T's)
Specialized Programs of Research Excellence (SPORE) Grants	•	Fewer new awards Decreases to non-competing awards
Intramural Research Program	• • •	Planned budget reductions Reduced hiring Decreased contractor utilization Trim programs

Resources about NCI budget and appropriations



Sept. 6, 2023 NCAB meeting: NCI budget overview www.videocast.nih.gov/watch=52268&start=3723



Updated budget and appropriations page: www.cancer.gov/about-nci/budget

NCI's Fiscal Year 2024 Budget Challenges and Interim Paylines Explained

Subscribe

November 15, 2023, by NCI Acting Director, Dr. Douglas R. Lowy

UPAH: Since this blog was posted on November 15, Congress posted another short-term continuing resolution that extends funding for the National Institutes of leadah of load fiscal years budget levels through features 2, 252 with the post. VLA charling Director Dr. Lowy describes key challenges that this That's budget presents to LCA and Is effects on Nich ability to support cancer research. No allos discusses newly announced interim polyties for comparing grants.



NCI *Bottom Line* blog post on FY24 budget outlook: www.cancer.gov/grants-training/nci-bottom-line-blog/



Leading Progress against Cancer NCI Fiscal Year 2025 Professional Judgment Budget Proposal

NCI Fiscal Year 2025 Professional Judgment Budget Proposal: www.cancer.gov/research/leading-progress

National Cancer Plan

Everyone has a role.

8 goals:

Prevent Cancer Detect Cancers Early Develop Effective Treatments Deliver Optimal Care Maximize Data Utility Eliminate Inequities Optimize the Workforce Engage Every Person



THE PRESIDENT AND FIRST LADY'S

CANCER MOONSHOT

ENDING CANCER AS WE KNOW IT

Goals of the reignited Cancer Moonshot

- Reduce U.S. cancer mortality rate by 50% by 2047
- Improve the experience of people and their families living with and surviving cancer



Recent wins – some examples



Recent wins and accomplishments in cancer research

- ★ ✓ First FDA approval of cell therapy in solid tumors (tumor-infiltrating lymphocytes for advanced melanoma)
- * ✓ Launch of <u>Self-collection for HPV testing</u> to Improve Cervical Cancer Prevention (SHIP) Trial Network
- ★ ✓ Launch of new Cancer Screening Research Network
- * ✓ Launch of new NCI Virtual Clinical Trials Office
 - ✓ New immunotherapy for endometrial cancer (hard-to-treat)
 - ✓ First immunotherapy approved for nasopharyngeal cancer; EBV vaccine studies underway
 - ✓ Targeted therapy for RET-positive lung, medullary, and thyroid cancers
 - ✓ First FDA-approved targeted therapy for children with high-risk Hodgkin lymphoma
 - First FDA-approved drug (immunotherapy) for advanced alveolar soft part sarcoma (ASPS), an extremely rare cancer that mainly affects adolescents and young adults
 - ✓ ...and more at NCI Cancer Currents blog

FIONAL CANCER INSTITUTE



Breakthrough in cellular therapy for solid tumors – pioneered by decades of NCI research

Tumor-infiltrating lymphocytes (TILs) for advanced melanoma


- First-ever FDA approval of cellular therapy for solid tumors
- Marks a new era of cancer treatment

Exemplary model of collaboration and translational science: basic science > clinical research > treatment development

Considerations: Scaling; application to other cancers; access



Pioneered by Dr. Steven A. Rosenberg NCI Center for Cancer Research ~40 years of basic science research



Contributes to National Cancer Plan goals:



New "SHIP" trial network on self-sampling for cervical cancer prevention announced at White House (January 25, 2024)



Readout of White House Cervical Cancer Forum

Last week, the Biden Cancer Moonshot hosted the White House Cervical Cancer Forum \nearrow to recognize Cervical Cancer Awareness Month and spur action on education, prevention, early detection, and treatment.

As part of the Forum, National Cancer Institute (NCI) Director Kimryn Rathmell announced a new NCI-supported trial to drive progress on cervical cancer prevention. The brand new 'Last Mile' Initiative, Self-collection for HPV testing to Improve Cervical Cance Prevention (SHIP) Trial Network / a aims to test the performance of heidel (N aim) and the formation of the set of

ess n, and et lancer

As part of the Forum, National Cancer Institute (NCI) Director Kimryn Rathmell announced a new NCI-supported trial to drive progress on cervical cancer prevention. The brand new 'Last Mile' Initiative, Self-collection for HPV testing to Improve Cervical Cancer Prevention (SHIP) Trial Network ↗ aims to test the performance of multiple self-collection devices for HPV, the leading driver of cervical cancer, so that cervical cancer screening can be brought closer to the people in the communities that are behind on screening.

www.whitehouse.gov/briefing-room

<u>Self-collection for HPV testing to Improve</u> Cervical Cancer <u>Prevention (SHIP)</u> Trial Network

- Great example of:
 - Broad collaboration within research and beyond, including federal and private sector
 - ✓ Addressing disparities
 - Engaging with the community, beneficiaries of research

Contributes to National Cancer Plan goals:





First large scale network on cancer screening launched

NCI Press Release

NIH launches research network to evaluate emerging cancer screening technologies

February 21, 2024



Goal: To evaluate emerging cancer screening technologies (e.g., multi-cancer detection blood tests) – with the ultimate aim to save lives.

CSRN is the first large scale network to focus on cancer screening.



Contributes to National Cancer Plan goals

New NCI Virtual Clinical Trials Office pilot program

NCI Media Advisory

NIH to address dwindling clinical trial patient enrollment with centralized staffing support

February 29, 2024



What:

• Centralized, remote staff support for NCI-supported clinical trials activities

Aims:

 Improve accrual and retention rate to trials – by addressing staffing challenges and burdens of clinical research

Status:

• 6 sites selected for initial pilot phase

Contributes to National Cancer Plan goals:



Childhood Cancer Data Initiative (CCDI) continues to make progress toward National Cancer Plan goals

- Recent progress
 - Molecular Characterization Initiative (MCI) expands enrollment to children newly diagnosed with advanced stage neuroblastoma
 - Includes Renal Medullary Carcinoma (RMC)
- Upcoming events
 - March CCDI Community Forum (first of the year) interactive Q&A seeks *your*/community input



CCDI continues to make important contributions to National Cancer Plan goals

WHAT IS THE CCDI MOLECULAR CHARACTERIZATION INITIATIVE?

- Provides state-of-the-art **molecular characterization at time of diagnosis** to inform optimal treatment decisions.
- A national collaboration between:
 - Childhood cancer community (including COG)
 - ✓ Advocates
 - ✓ Pediatric oncologists
 - ✓ Researchers
 - ✓ Data scientists
 - ✓ Children, adolescents, and young adults with cancer
 - ✓ Families



Closing thoughts

Although the budget outlook is not ideal...

We will work together across the cancer community – creatively, collaboratively, and efficiently – to make the best decisions given the tough reality.

Our work is ultimately for the benefit of people, patients and families touched by cancer.

We will use the National Cancer Plan as our roadmap toward ending cancer as we know it.



Working together to assemble puzzle. Image generated by AI.

Thank You!

www.cancer.gov www.cancer.gov/espanol 1-800-4-CANCER NClinfo@nih.gov @NCIDirector @TheNCI

